Estela Noguera-Ortega (0000-0001-6507-0673)

Personal information

Biography

Dedicated researcher with thorough experience in in vitro and in vivo cancer immunotherapy and tumor immunology. Track record of publications in peer-reviewed journals and book chapters and author of a patent. Expertise in cell culture, immunoassays, microbiology, electronic & confocal microscopy, and lung, melanoma and bladder cancer mouse models. Proficient at quickly learning new laboratory skills, as well as enthusiastic about teaching lab members. Organized and detail-oriented. Always approaching projects with a hard-working nature.

Activities

Collapse all

University of Pennsylvania: Philadelphia, PA, US

2019-01-08 to present | Post-doc (Pulmonary, Allergy, and Critical Care Division, Perelman School of Medicine)

Employment

Estela Noguera-Ortega

https://orcid.org/0000-0001-6507-0673

Personal information

Other IDs

Biography

Activities

Employment (2)

University of Pennsylvania: Philadelphia, PA, US

University of Pennsylvania: Philadelphia, PA, US

Education and qualifications (1)

Universitat Autònoma de Barcelona: Barcelona, Catalunya, ES

Professional activities (1)

American Association for Cancer Research: Philadelphia, PA, US

Works (26)

Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors

Data from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [<sup>18</sup>F]AlF-FAPI-74

Data from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [<sup>18</sup>F]AlF-FAPI-74

Supplementary Data from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [<sup>18</sup>F]AlF-FAPI-74

Supplementary Data from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [<sup>18</sup>F]AlF-FAPI-74

Supplementary Data from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [<sup>18</sup>F]AlF-FAPI-74

Supplementary Data from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [<sup>18</sup>F]AlF-FAPI-74

Supplementary Data from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [<sup>18</sup>F]AlF-FAPI-74

Supplementary Data from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [<sup>18</sup>F]AlF-FAPI-74

Supplementary Figure from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [<sup>18</sup>F]AlF-FAPI-74

Supplementary Figure from Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [<sup>18</sup>F]AlF-FAPI-74

Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment

Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma

Mycobacteria-Based Vaccines as Immunotherapy for Non-urological Cancers

CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment

ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.

PPT1 Promotes Tumor Growth and Is the Molecular Target of Chloroquine Derivatives in Cancer.

Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice

Mycobacteria-Derived Agents for the Treatment of Urological and Renal Cancers

Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role?

Mycobacteria Clumping Increase Their Capacity to Damage Macrophages.

Mycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment

Nonpathogenic Mycobacterium brumae Inhibits Bladder Cancer Growth In Vitro, Ex Vivo, and In Vivo

γ-Irradiated mycobacteria enhance survival in bladder tumor-bearing mice although they are less efficacious than live mycobacteria.

Killed but Metabolically Active Mycobacterium bovis bacillus Calmette-Guerin Retains the Antitumor Ability of Live bacillus Calmette-Guerin

Peer review (32 reviews for 6 publications/grants)